CLINICAL TRIAL

Purpose of the study: to evaluate the impact of complex treatment and medical rehabilitation of after stroke patients based on development and clinical validation of a new WO:EX therapy method.

Inclusion criteria: 1) clinically validated diagnosis of cerebral infarction with hemiparesis; 2) age over 40 years; 3) stroke, corresponded by 7-15 points of The National Institutes of Health Stroke Scale; 4) the time elapsed from the moment of the brain accident - from 3 weeks to 6 months; 5) willingness of the patient to participate in the study.

Exclusion criteria: 1) clinically confirmed COVID-19; 2) cognitive impairments; 3) 7 days hospitalization or less; 4) moderately severe pain; 5) any negative complaints that arise during the course of the study; 6) refusal to participate in the study.

Study involved 57 (n=57) after stroke patients: 30 (53%) patients included into main group (undertaken WO:EX THERAPY in combination with standard treatment), and 27 (47%) patients into control group (with standard treatment)

Before (index 1) and after (index 2) treatment, all participants were evaluated by:

1)Barthel Index (BI)

2)Modified Rivermead Mobility Index (MRMI)

3)Scandinavian Stroke Scale (SSS)

4)ΔSSS - difference between SSS2 and SSS1

5)10-Meter Walking Test (10MWT)

6)Fugl-Majer Scale (FMS)

7)Fatigue Severity Scale (FSS)

8)National Institutes of Health Stroke Scale (NIHSS)

Curve of operational characteristics (ROC) of the variable ΔSSS in assessing the effectiveness of the therapy

CONCLUSION:

WO:EX therapy increases the effectiveness of standard stroke therapy program by 37% (p = 0,008), due to significant effects on the state of walking function and movement-related functions (OR = 1.37; 95 %CI: 1.1-1.78).